Meridian Bioscience Stock

Meridian Bioscience Total Assets

The Total Assets of Meridian Bioscience (VIVO) as of Sep 12, 2026 is 463.10 M USD. In the previous year, Total Assets was 449.72 M USD — a change of 2.97% (higher).

Total Assets

463.10 MUSD

YoY

2.97%

Last updated:

Total Assets of Meridian Bioscience is 2026 463.10 M USD. Total Assets of Meridian Bioscience was 2025 449.72 M USD. It decreases by 2.97% higher compared to the previous year.

The Meridian Bioscience Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2015
183.30 M USD
Jan 1, 2016
252.00 M USD
Jan 1, 2017
249.80 M USD
Jan 1, 2018
251.40 M USD
Jan 1, 2019
325.50 M USD
Jan 1, 2020
405.30 M USD
Jan 1, 2021
449.72 M USD
Jan 1, 2022
463.10 M USD
The Meridian Bioscience Total Assets history
YEARTotal AssetsYoY
463.10 MUSD+2.97%
449.72 MUSD+10.96%
405.30 MUSD+24.52%
325.50 MUSD+29.47%
251.40 MUSD+0.64%
249.80 MUSD-0.87%
252.00 MUSD+37.48%
183.30 MUSD+3.62%
176.90 MUSD
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Total Assets of Meridian Bioscience is 463.10 M USD in 2026.

Total Assets of Meridian Bioscience changed from 449.72 M USD to 463.10 M USD, representing a 2.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Meridian Bioscience

All Key Metrics — Meridian Bioscience